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Materials and Methods: A comparative study between two 
groups matched for age, surgical technique, size, nodal 
status and adjuvant treatment was performed. The control 
group received conservative surgery and standard EBRT 50-60 
Gy in 5-6 weeks. The experimental group received 
conservative surgery with IMIMBI for perioperative PBI 34 Gy 
in 10 fractions. 
Results: A total of 160 patients, 80 in control group and 80 in 
the experimental were analyzed. The median age and follow 
up were 56 vs. 60 years (p> 0.05) and 55 vs. 33 months 
(p<0.05), respectively. Surgical technique in control vs. 
experimental group includes Lumpectomy alone in 10% of 
each group, lumpectomy with sentinel lymph node dissection 
in 82% vs 88% and lumpectomy with axillary dissection in 5% 
vs. 1%, respectively. The median tumor size was 11 mm vs. 
12 mm in control and experimental group, and all patients 
were pN0. Median number of catheters were 9 (6-14), double 
plane implant in 100%, median D90 of 3.3 Gy median V100 
and V150 of 35 and 10 cc respectively with DHI 0.72. Minor 
complication (infection, seroma, bleeding) were recorded in 
14 patients (8.7%) seven in each group and major 
complication (reintervention due to bleeding o dehiscence) in 
2 patients (1.2%) one in each group. Median operative time, 
hospital stay and time from surgery to end of radiation were 
97 '(range 27'-309') vs. 123' (range 72'-234'), 2 days for each 
group and 130 vs. 11 days in the control and experimental 
groups respectively. No local failure or distant failure were 
observed and excellent cosmetics results were recorded in 
more than 80% of both groups.  
Conclusions: The optimal time to perform MIT is 
intraoperative because is safe, fast, effective and provides a 
significant improvements in logistical issues like reduction in 
overall locoregional treatment. Also allows to take advantage 
of excellence in dosimetry derived of MIT avoiding a second 
invasive procedure.   
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Purpose/Objective: Accelerated partial breast irradiation 
(APBI) is used increasingly. Clinical Target Volume (CTV) 
definition with multicatheter implant is not easy when closed 
cavity technique is used for breast conserving therapy. A 
perioperative implant allows us to know the right location of 
the tumour bed and CTV. We analyze clinical and dosimetric 
aspects of CTV definition with perioperative brachytherapy 
for APBI. 
Materials and Methods: We review 10 cases of women with 
low risk breast carcinoma that underwent conserving surgery. 
During the same procedure, with the opened cavity, a 
perioperative multicatheter implant with parallel plastic 
tubes was performed, using the reference of the surgeon to 
place the tubes at the exact position. One central catheter, 
or guide-tube, was inserted perpendicular to the skin scar at 
the bottom where the tumour was located, and then the 
surgeon closed the cavity usually marked with clips. The rest 
of the tubes were inserted forming triangles in two or three 
planes to cover a security margin. A planning CT scan was 
performed 2-4 days later. The area above the guide-tube was 
drawn with central clips if present, and a margin of 1-1.5cm 
was expanded avoiding 1cm from skin and pectoral muscle. 
The resulting volume was adjusted to cover the lateral 
plastic tubes with a margin of a few mm to obtain the CTV. 
The prescription dose was 4 Gy to the CTV per eight fractions 
twice a day. 
Results: Four patients required nine catheters in two planes 
and six patients 10-12 catheters in three planes. The mean 
CTV volume was 83.9cc (67.7-116.6cc). Mean dose non-
uniformity ratio (DNR) was 0.32 (0.28-0.35). Mean dose to the 
90% of the CTV (D90) was 4’04Gy. Maximum dose per fraction 
to the lung was 1.75Gy (0.75-2.28Gy), and to the heart in 5 
left breasts was 1 Gy (0.65-1.3Gy). Clips were placed in six 
cases and half of them were far from the implanted area and 
were not included in the CTV. In six cases several small air 
cavities were detected some of them outside of the CTV 
area.  
Conclusions: Perioperative implants are the most exact way 
to define the right CTV. The guide-tube is a good system to 
define the central area of the CTV in the planning CT when 
the cavity is closed. Clips and small air cavities are related to 
the area manipulated by the surgeon, the surgical bed, but 
are not always useful to define the tumour bed, which is the 
real area to be irradiated (Fig 1). With perioperative 
brachytherapy, less number of catheters are required and the 
CTV volume is smaller than usual with postoperative 
multicatheter technique for APBI.  
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Purpose/Objective: To estimate intra- and inter-fraction 
HRCTV and OAR dose variability in two consecutive day IGABT 
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fractions in cervical cancer intracavitary-intersticial MR/CT-
based BT. 
Materials and Methods: 45 consecutive patient cervical 
cancer patients treated between January 2013 and May 2014 
were considered. FIGO stage distribution was the following: 4 
had stage IB, 33 had IIB (7 out of 33 with distal parametrial 
invasion), 7 had IIIB tumors (all because parametrial invasion 
up to pelvic wall) and 1 had IVA tumor. Treatment consisted 
in 3DCRT (45 Gy in 25 fr.) with concomitant chemotherapy 
(weekly cisplatin 40 mg m2) followed by MR/CT based IGABT 
(4 fractions of 7 Gy within 2 insertion with 1 week interval 
with Elekta Utrecht applicator). A stringent bladder filling 
and bowel preparation protocol is routinely used at our 
institution.  
At 1st application, T2 MRI and i.v. contrasted CT (day 1 CT) 
with applicator in place were performed with an interval of 
30 min (MR slice thickness 3,5 mm without gaps; CT thickness 
2mm). Direct applicator reconstruction on MR images was 
performed and dose optimized to target volumes and OAR 
delineated on MR according GEC ESTRO recommendations. 
After patient treatment, original MR and CT datasets were 
fused based on the applicator coordinates and HRCTV 
contours from MR dataset transferred to CT. Further OARs 
were re-delineated on day 1 CT, applicator reconstructed and 
the original MR optimized plan recalculated on CT images. 
DVH parameters for OAR delineated on day1 CT were 
recorded (Intrafraction variability). 
On the following day, a second CT was performed (2mm slice 
thickness). Furthermore day 2 CT was fused with the day 1 
CT on the applicator coordinates and the original MR based 
HRCTV contours (present on CT day 1) transferred from day 1 
CT to day 2 CT. OAR were then delineated on day 2 CT and 
the original MR optimized plan recalculated on CT day 2 
images. DVH parameters for OAR delineated on day 2 CT 
were recorded (interfraction variability). 
We assume in our study design that intra-fraction variability 
is predominantly due to systematic contouring uncertainties 
introduced by OAR delineation on different imaging 
modalities and less importantly by eventual OAR movements. 
We expect that interfraction variability to be of higher 
magnitude and predominantly due to OAR movements. 
Results: Results are summarized in Tab 1. The magnitude of 
intra- and inter-fraction variability is very low probably with 
no clinical relevance in the vast majority of patients. Intra- 
and inter-fraction HRCTV and OAR variability is similar. 
 
 
 
Conclusions: Presented data together with previously 
published reports from Lang S. et al. (R&O 2013) seems to 
suggest that, in a protocol of four fractions within 2 different 
applications no re-planning is needed to safely deliver the 
second BT fraction of each application if an OAR filling 
protocol is applied. Nevertheless before applying this concept 
in the clinical routine more data are warranted. 
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Purpose/Objective: To review doses achieved in the 
treatment of locally advanced cervical cancer at the 
Northern Ireland Cancer Centre compared to standards set by 
GEC-ESTRO since the introduction of image guided high dose 
rate brachytherapy.  
To compare outcomes both in terms of recurrence and 
survival and long term toxicity with published outcomes. 
Materials and Methods: Retrospective review of clinical 
notes and radiotherapy prescriptions of all patients with 
locally advanced cervical ca treated at the Northern Ireland 
Cancer Centre from 2008-2013. 
Results: 188 patients with locally advanced cervical cancer 
were treated with radical intent with a median age 47.4 
years (23.3 -79.80.4). Median follow up is 25.5 months. 
180/188 had concurrent cisplatin. CT scanning was carried 
out after each intra-cavity insertion and used to contour OAR 
and to identify Point A. Equivalent doses in 2Gy fractions 
(EQD2) were calculated combining external beam 
radiotherapy and brachytherapy doses. αβ 10 was used for 
tumour and αβ3 used for organs at risk. Median dose to point 
A EQD2 was 76.4Gy (66.5-79.3) with 68 patients receiving less 
than <75Gy. Median dose to rectum was 65.5Gy (57.2-
82.6)with 3 patients receiving more than 75Gy.Median dose 
to bowel was70.7Gy (55.5-79.2) with 26 patients receiving 
over 75Gy.Median dose to bladder was 80.5Gy (551-97.8) with 
3 receiving greater than 95Gy. Pelvic recurrence at 3 years 
was 12.2% with distant metastasis 8.5% . Overall Survival (OS) 
at 3years was 74%. There was a documented pelvic or distant 
recurrence at 3years in 30.8% of node positive patients and 
9.45% of node negative patients(p=0.005). Grade 3/4 late 
bowel and bladder toxicity of 7.9 and 6.3% respectively were 
documented. There were no significant differences in dose 
delivered in those patients who developed bladder or bowel 
toxity compared to those who did not. Mean dose to bowel in 
those who had Grade 3/4 toxicity was 71.2Gy and 70.0Gy 
without (p=0.20). Mean dose to bladder in those with GD3/4 
bladder toxicity was78.9Gy and 79.6Gy without (p=0.81). 
Repeat MRI in the final week of radiotherapy was introduced 
in 2010 and performed in 97 patients. In those who had a 
complete response at final week MRI (30) there was 1 pelvic 
recurrence compared to 22 pelvic recurrences in those who 
had partial response or stable disease(77) (p=.0035).  
